The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.
Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels
The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.